LAMP2A Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LAMP2A Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Lysosomal-Associated Membrane Protein 2A</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>[LAMP2](/genes/lamp2)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P13473](https://www.uniprot.org/uniprot/P13473) (isoform A)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>410 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~45 kDa (core), ~120 kDa (glycosylated)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq24</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Lysosomal membrane</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">LAMP2A gene therapy</td>
<td>AAV-mediated LAMP2A overexpression in vulnerable neurons</td>
</tr>
<tr>
<td class="label">CMA activators</td>
<td>Small molecules that stabilize LAMP2A at lysosomal membrane</td>
</tr>
<tr>
<td class="label">Cholesterol reduction</td>
<td>Statins to normalize lysosomal membrane lipid composition</td>
</tr>
<tr>
<td class="label">AR7 and derivatives</td>
<td>Retinoic acid receptor alpha agonists that transcriptionally upregulate LAMP2A</td>
</tr>
<tr>
<td class="label">Hsc70 modulators</td>
<td>Enhance substrate delivery to LAMP2A</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">257 edges</a></td>
</tr>
</table>
Pathway Diagram
Mermaid diagram (expand to render)
LAMP2A (Lysosomal-Associated Membrane Protein 2A) is the isoform A splice variant of the [LAMP2](/genes/lamp2) gene product, serving as the rate-limiting receptor for chaperone-mediated [autophagy](/entities/autophagy) (CMA). Unlike macroautophagy, which engulfs bulk cytoplasmic material, CMA selectively targets individual proteins bearing a KFERQ-like pentapeptide motif for direct translocation across the lysosomal membrane["@eskelinen2006"]. LAMP2A is the only known receptor for this pathway: substrate proteins are recognized by cytosolic [Hsc70](/proteins/hsc70-protein), delivered to LAMP2A on the lysosomal surface, and translocated through a LAMP2A multimer channel into the lysosomal lumen for degradation["@bandyopadhyay2008"]. CMA dysfunction, driven primarily by age-dependent LAMP2A decline, has emerged as a central mechanism in [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and other proteinopathies where failed clearance of pathological proteins drives neuronal death["@cuervo2014"][@xilouri2016].
Structure
LAMP2A is a type I transmembrane protein with three distinct regions:
Luminal Domain
The large luminal domain (~350 residues) is heavily glycosylated with N-linked and O-linked glycans, forming a glycan coat that protects the lysosomal membrane from resident hydrolases. This domain is shared with LAMP2B and LAMP2C isoforms and contains a proline-rich hinge region[@eskelinen2006].
Transmembrane Domain
A single transmembrane helix anchors LAMP2A in the lysosomal membrane. This segment is critical for LAMP2A multimerization — substrate translocation requires assembly of LAMP2A monomers into a ~700 kDa translocation complex at the lysosomal surface[@bandyopadhyay2008].
Cytoplasmic Tail
The 12-amino-acid cytoplasmic tail is unique to the LAMP2A isoform (generated by alternative splicing of exon 9A) and is the functional element that distinguishes LAMP2A from LAMP2B/C. This tail contains four positively charged residues essential for substrate binding and contains the critical Gly-Tyr doublet required for CMA activity. The cytoplasmic tail directly binds Hsc70-substrate complexes, initiating the translocation process[@eskelinen2006][@kaushik2018].
Normal Function
LAMP2A is the sole receptor and translocation channel for CMA. The pathway operates through a defined sequence[@bandyopadhyay2008][@cuervo2014]:
Substrate recognition: Cytosolic [Hsc70](/proteins/hsc70-protein) recognizes proteins bearing KFERQ-like motifs (present in ~30% of cytosolic proteins)
Receptor binding: The Hsc70-substrate complex docks on the LAMP2A cytoplasmic tail
Substrate unfolding: The substrate protein must be unfolded before translocation, assisted by Hsc70 and co-chaperones
LAMP2A multimerization: Binding triggers assembly of LAMP2A monomers into a ~700 kDa translocation complex
Translocation: The unfolded substrate passes through the LAMP2A channel into the lysosomal lumen
Luminal degradation: Lysosomal Hsc70 (lys-Hsc70) pulls the substrate into the lumen; resident proteases complete degradation
Complex disassembly: After translocation, the LAMP2A multimer disassembles, and monomers are available for recyclingCMA Substrates in the Brain
Key neuronal CMA substrates include:
- [Alpha-synuclein](/proteins/alpha-synuclein): Contains a KFERQ-like motif (VKKDQ) at residues 95-99
- [Tau protein](/proteins/tau): Contains multiple CMA-targeting motifs
- [GAPDH](/proteins/gapdh-protein): Glycolytic enzyme degraded by CMA under oxidative stress
- [Huntingtin](/proteins/huntingtin) fragments: Polyglutamine-expanded fragments are CMA substrates
- MEF2D: Transcription factor essential for neuronal survival[@xilouri2016]
Regulation of LAMP2A Levels
CMA activity is controlled primarily through LAMP2A protein levels at the lysosomal membrane, not through transcriptional regulation. LAMP2A undergoes constitutive degradation in the lysosomal lumen through cathepsin A-mediated cleavage, and is also cleaved by metalloproteinases in lipid microdomains. During CMA activation (starvation, oxidative stress), LAMP2A degradation slows, increasing receptor density and CMA capacity[@kaushik2018].
Role in Neurodegeneration
Parkinson's Disease
CMA dysfunction is a major contributor to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:
- Alpha-synuclein clearance failure: Wild-type [alpha-synuclein](/proteins/alpha-synuclein) is normally degraded by CMA through its KFERQ-like motif. However, pathological alpha-synuclein species — including A30P and A53T mutants, dopamine-modified forms, and oligomeric species — bind LAMP2A but fail to translocate, blocking the receptor for other substrates[@cuervo2004]. This creates a toxic gain-of-function: not only is alpha-synuclein itself not cleared, but CMA of all other substrates is inhibited.
- LAMP2A decline with age: LAMP2A protein levels decrease progressively in the aging brain, particularly in dopaminergic [neurons](/entities/neurons) of the [substantia nigra](/brain-regions/substantia-nigra). This age-dependent decline correlates with alpha-synuclein accumulation and increased PD susceptibility[@cuervo2014][@xilouri2016].
- Protective LAMP2A overexpression: Viral-mediated LAMP2A overexpression in rat substantia nigra protects dopaminergic neurons from alpha-synuclein toxicity and prevents neurodegeneration in PD models[@xilouri2013].
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease), CMA dysfunction contributes to [tau](/proteins/tau) pathology:
- Tau degradation: [Tau](/proteins/tau) contains CMA-targeting motifs and is partially degraded through LAMP2A-mediated CMA. Hyperphosphorylated tau, however, shows reduced CMA degradation efficiency
- Compensatory CMA activation: Early AD stages show compensatory upregulation of LAMP2A, but this compensation fails as disease progresses
- APP processing: Components of the [amyloid precursor protein](/entities/app-protein) ([APP](/proteins/app)) processing machinery are regulated by CMA[@xilouri2016]
Huntington's Disease
Mutant huntingtin fragments with expanded polyglutamine tracts are CMA substrates but, similar to mutant alpha-synuclein, can block the LAMP2A translocation complex. CMA upregulation through LAMP2A overexpression ameliorates huntingtin aggregation in cellular models[@cuervo2014].
Aging and CMA Decline
The most consistent change in CMA across aging and neurodegeneration is the progressive decline in LAMP2A levels at the lysosomal membrane. This decline is driven by changes in lysosomal membrane lipid composition (increased cholesterol content) that accelerate LAMP2A degradation. Genetic restoration of LAMP2A levels in aged mouse liver restores CMA activity and improves proteostasis[@kaushik2018][@zhang2008].
Therapeutic Targeting
See Also
- [Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
- [Tau Protein](/proteins/tau)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Proteostasis](/mechanisms/proteostasis)
External Links
- [UniProt: P13473](https://www.uniprot.org/uniprot/P13473)
- [NCBI Gene: LAMP2](https://www.ncbi.nlm.nih.gov/gene/3920)
- [GeneCards: LAMP2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=LAMP2)
References
[Eskelinen EL, Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy (2006)](https://pubmed.ncbi.nlm.nih.gov/16949/)
[Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM, The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane (2008)](https://pubmed.ncbi.nlm.nih.gov/18539147/)
[Cuervo AM, Wong E, Chaperone-mediated autophagy: roles in disease and aging (2014)](https://pubmed.ncbi.nlm.nih.gov/24079773/)
[Xilouri M, Brekk OR, Stefanis L, Autophagy and alpha-synuclein: relevance to Parkinson's disease and related synucleinopathies (2016)](https://pubmed.ncbi.nlm.nih.gov/26344184/)
[Kaushik S, Cuervo AM, The coming of age of chaperone-mediated autophagy (2018)](https://pubmed.ncbi.nlm.nih.gov/30022913/)
[Cuervo AM, Stefanis L, Bhatt DK, et al, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy (2004)](https://pubmed.ncbi.nlm.nih.gov/15331592/)
[Xilouri M, Brekk OR, Landeck N, et al, Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/23487764/)
[Zhang C, Bhatt DK, Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function (2008)](https://pubmed.ncbi.nlm.nih.gov/18510934/)